Skip links

Corporate communications

PharmaCielo Announces Q1 2023 Financial Results

May 29, 2023 The Company has products in various stages of testing and sales with more than 40 customers in 11 countries, with continued growth expected for the year. Q1 2023 revenue of $786,498; Adjusted EBITDA loss of $1.9 million. PharmaCielo continues to focus on

PharmaCielo Announces TSX Venture Exchange Approval of Warrant Extension

November 22, 2022 TORONTO, Canada and RIONEGRO, Colombia (November 22, 2022) – PharmaCielo Ltd. (“PharmaCielo”or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced

PharmaCielo Announces Q3 2022 Financial Results

October 31, 2022 In the first nine months of 2022, PharmaCielo has made shipments to 23 customers in nine countries, with continued growth expected for 2023. The Company has more than doubled Revenue to $3.8 million in the first nine months of 2022, compared to